Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Launch By Indian Drug Maker Blocked By New Patent Move

This article was originally published in PharmAsia News

Executive Summary

India's Lupin may not be able to launch its generic version of the blood-pressure drug Altace (ramipril) in June as planned because of an action that could affect all Indian generics makers. Lupin had won its patent challenge against King Pharmaceuticals and Sanofi-Aventis, freeing it to market its generic when the patent expires June 7, but King has filed a citizen petition on a new patent. Other Indian drug makers have been assertive in trying to break patent protection in the United States, but the brand makers are fighting back. King's action requires an FDA review of the petition. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts